Javier Bleichmar

Choosing the Remedy the Case Can Support

The Teva securities litigation and the Tesla director-compensation litigation produced different forms of relief for different legal injuries. Teva created a cash fund for eligible investors who bought securities during a defined period and submitted valid claims under an allocation plan. Tesla was a derivative action brought on the company’s behalf; its relief returned value to Tesla and changed how director compensation would be handled.

Bleichmar co-founded Bleichmar Fonti & Auld and leads its United States case-evaluation and securities-litigation practices. He evaluates who was injured, who owns the claim, what proof is available, which court can hear it, and whether the likely remedy justifies the cost and risk of litigation. That analysis identifies the plaintiff, legal theory, forum, and requested relief supported by the available evidence.

Case evaluation continues after filing. Pleading defines the viable theories, class certification establishes the scale of common proof, discovery tests corporate documents and witness accounts, experts measure market or corporate impact, and settlement design translates the developed evidence into an administrable remedy. At each stage, the claim, proof, client, and requested relief must remain aligned.

Teva required class treatment of investor losses. Tesla required a corporate remedy in a derivative action. MF Global required separate agreements with several defendant groups to function within one coordinated recovery. Bleichmar’s role in each matter joined the legal owner of the claim to the form of relief the proceeding could deliver.

Teva: Testing a Securities Theory Through Discovery

Teva investors alleged that public statements about the company’s financial performance concealed conduct in the generic-drug market and that later disclosures caused market losses. The litigation lasted about five years and required the investor team to connect the challenged statements to the concealed conduct, then connect corrective information to market loss.

The case survived dismissal and reached class certification. The district court certified the investor class, and the Second Circuit left that ruling in place at the interlocutory stage. Certification established a coordinated route for the defined group of investors and allowed Bleichmar’s team to develop merits and damages evidence on a classwide record.

Fact and expert discovery included company documents, witness testimony, depositions, economic analysis, and preparation for summary judgment. The team tested the investor theory against internal records and competing accounts of the market reaction, refining the chronology and damages analysis as the evidence developed.

The parties agreed to a $420 million cash settlement. The court granted final approval on June 2, 2022, creating a court-supervised payment process for eligible investors under the approved allocation plan. By settlement, Bleichmar’s team had preserved the case through dismissal, secured class certification, completed substantial fact and expert discovery, and prepared for summary judgment.

Tesla: Value and Governance Returned to the Corporation

In the Tesla derivative action, shareholders alleged that directors awarded themselves excessive compensation through a conflicted process. Because the claims belonged to Tesla, the corporation was the beneficiary of the settlement rather than individual shareholders receiving pro rata payments.

The relief included cash and stock returned by directors, cancellation of unexercised options, compensation the directors agreed to forgo, limits on future director pay, and governance procedures for reviewing and approving later compensation. The Delaware Court of Chancery approved the resolution in January 2025.

The terms separated restitution for past awards from restraints governing unexercised options and future compensation. Review procedures established how later director-pay decisions would be authorized and evaluated. Returned cash, returned stock, option cancellation, compensation forgone, future-pay limits, and governance commitments remained distinct parts of the corporate remedy.

The completed package paired restitution with enforceable restraints and review procedures governing future compensation decisions. Teva provided eligible investors with a cash-claims process; Tesla placed the benefit inside the corporation whose claims the shareholders pursued.

MF Global: Coordinated Recoveries Exceeding $234 Million

After MF Global collapsed, investors pursued securities claims against officers, directors, underwriters, and an auditor. The litigation produced settlements totaling more than $234 million from several defendant groups.

The components included $74 million from certain underwriters, $64.5 million from officers and directors, $65 million from PricewaterhouseCoopers, approximately $29.825 million from another underwriter group, and an additional smaller settlement. Each agreement addressed the claims, defenses, and payment source associated with a particular defendant group.

Bleichmar’s team coordinated defendant-specific claims, releases, contribution rights, continuing discovery, approval, and administration across the separate payment sources. The agreements preserved the value obtained from each settling group while the remaining work continued.

Court-approved plans combined the recoveries, matched released claims to the defendants who paid, defined eligible investors, and directed distribution. Bleichmar’s work connected several legal instruments to one administration structure, moving each agreement from negotiation through approval and payment.

Case Evaluation Across Forums

Teva, Tesla, and MF Global required different choices about claimant, forum, proof, and remedy. Teva required a federal securities class to connect investor transactions, public statements, market reaction, and loss; Tesla required shareholders to proceed derivatively for relief belonging to the corporation; MF Global required defendant-specific settlements to be coordinated into one distribution plan. Bleichmar’s case evaluation matches the legal owner of the claim to the forum, procedure, evidence, and beneficiary of the remedy before litigation proceeds.

He earned his undergraduate degree from the University of Pennsylvania and his law degree from Columbia Law School, where he was a Harlan Fiske Stone Scholar and worked on the Columbia Journal of Law and Social Problems. Bleichmar is admitted in Connecticut and New York, before the United States Supreme Court, and in several federal appellate courts. He is a native Spanish speaker and fluent in French.